Article
Brodalumab for moderate-severe hidradenitis suppurativa: an open-label multicentric cohort study in real clinical practice
2023-05-09
Abstract excerpt
<title>Abstract</title> <p><bold>Introduction</bold> The use of biological therapy is becoming increasingly common in patients with hidradenitis suppurativa (HS). Levels of serum TNF-alfa and IL17 support the role of an immune system dysregulation in the pathogenesis of HS. Brodalumab targets the receptor A of IL-17, thus having a promising role in the treatment of HS. <bold>Material and methods</bold> A multicen...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 59bf3b1d-2c1e-5a3d-b9ba-43ba1d92cbc6
- DOI
- 10.21203/rs.3.rs-2887055/v1
